Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
An orally active dual CBP/p300 degrader targets core dependencies of myeloma, has anti-proliferative and pro-apoptotic activity, reduces tumor growth in pre-clinical xenograft models, and shows synergy with dexamethasone.”
Title: An orally active dual CBP/p300 degrader targets core dependencies of multiple myeloma
Authors:Praveen Kumar Tiwari, Bomin Ku, Drew A. Harrison, Sarah Rizvi, Samuel Ojeda, Jessica Duffy, Leonie Cluse, Jennifer R. Devlin, Nenad Bartonicek, Olga Motorna, Ann-Sophie Koglin, Barbara Karakyriakou, Kaitlyn Gagnon, Ramya S. Iyer, Regina Egan, Pat Greninger, Lauren Benz, Caroline Greco, Julia Norton, Amruth Kumar, Eric F. Zaniewski, Soroush Hajizadeh, Robert Morris, Genna Mullen, Ajinkya S. Kawale, Sangwon Min, Sai Reddy Doda, Raghu Vannam, Lee Zou, Wilhelm Haas, Abner Louissaint Jr., Ricky W. Johnstone, Christopher J. Ott
You can read the Full Article on Cell Reports.
You can find other articles featuring Robert Orlowski on OncoDaily.
